Table 3.
Canonical pathways impacted by benzene exposure.
| Pathway* | Genes | Affymetrix | Illumina | Common | |||
|---|---|---|---|---|---|---|---|
| p-value† | No. Genes | p-value | No. Genes | p-value | No. Genes | ||
| Death receptor Signaling | BCL2, CFLAR, CRADD, FASLG, IKBKE, NFKB2, TNFRSF1A | - | - | 0.016 | 7 | - | - |
| ERK/MAPK signaling | DUSP1, DUSP4, FOS, MYC, PIK3R1, PPARG, PPP1CB, PPP1R10, PRKAR2B, RPS6KA1, SRC, STAT3 | - | - | 0.024 | 12 | - | - |
| Ganglioside biosynthesis | ST3GAL1, ST3GAL4, ST3GAL5, ST6GALNAC2, B3GALT4, ST8SIA4 | 0.046 | 4 | 0.00034 | 5 | 0.043 | 2 |
| Globoside metabolism | B3GALT3, HEXA, ST3GAL1, ST8STA4 | - | - | 0.022 | 4 | - | - |
| Glycerolipid metabolism | AGPAT4, AGPAT6, CERK, DHRS9, DGAT2, GK, LAC89944, LPL, PPAP2B | - | - | 0.026 | 9 | 0.019 | 6 |
| Glycerophospholipid metabolism | CERK, PPAP2B, HMOX1, PAFAH1B1,PLAG2G7 | - | - | - | - | 0.017 | 5 |
| Il-10 signaling | CCR5, FOS, HMOX1, IKBKE, IL1R2, JUN, NFKB2, RELB, STAT3 | - | - | 0.0031 | 9 | 0.004 | 6 |
| IL-6 signaling | ABCB1, FOS, IKBKE, IL1R2, JUN, MAPKAPK2, NFKB2, STAT3, TNFRSF1A | - | - | 0.0081 | 9 | - | - |
| PDGF signaling | ABL1, FOS, JUN, MYC, PIK3R1, SRC, STAT3 | - | - | 0.021 | 7 | - | - |
| PPAR signaling | FOS, IKBKE, IL1R2, JUN, NCOA1, NFKB2, PPARG, RXRA, STAT5A, TNFRSF1A | - | - | 0.0017 | 10 | - | - |
| Protein ubiquitination | ANAPC1, BAP1, BIRC4, BTRC, CUL1, IFNG, PSMA3, PSMB4, PSMC2, PSMC4, PSMD2, PSMD4, PSMD11, PSMD12, SMURF2, UBC, UBE2I, UBE2Q1, USP3, USP18, USP24, USP28, USP33, USP36, USP39, USP47, USP9X | 0.0017 | 27 | - | - | - | - |
| Sterol biosynthesis | FDFT1, HMGCR, MVD, SC5DL | - | - | 0.025 | 4 | 0.019 | 3 |
| Toll-like receptor signaling | FOS, JUN, NFKB2, RELB, TLR2, TOLLIP | - | - | 0.031 | 6 | - | - |
*
Derived from Ingenuity® Pathway Analysis of Affymetrix, Illumina and common datasets.
†
Fischer's exact test is used to calculate the p-value.